“Global Vaccine Contract Manufacturing Market Set To Grow To $1.3bn By 2022″says Visiongain report.

19 July 2018
Pharma

Visiongain’ has launched a new pharma report Global Vaccine Contract Manufacturing Market Report 2018-2028 : Leading Countries, Technologies and Companies

The vaccine manufacturing technology and services market has experienced considerable growth over the past decade. Vaccines are a global healthcare success, currently driven by disease burden and the expanding global population. Strong growth will be seen in the therapeutic vaccines market, driven by development of vaccines for indications such as cancer. Our research suggests that demand and technological developments in this industry will drive changes in the methods and management of vaccine production. The global vaccine market will experience strong growth throughout the forecast period, as will that for outsourced vaccine manufacturing.

The lead analyst of the report commented “The transfer of vaccine technology is more difficult compared to other industries. This is the reason why the US and the EU5 have such a dominant market share of the vaccine contract manufacturing market. Vaccine manufacturing is highly technical with stringent regulatory and quality standards which have mainly kept it within regions which have the technology and regulatory framework to accommodate production.

Although off-shoring to lower costs is very popular for other industries, the vaccine contract manufacturing market in emerging markets will mainly show growth through domestic demands, at least in the first half of the forecast period, as emerging markets still grapples with international vaccine manufacturing practises and new technology platforms.”

Leading companies featured in the report include Baxter BioPharma Solutions, Boehringer Ingelheim, Catalent, Charles River Laboratories, IDT Biologika, Lonza, Meridian Life Science, Sigma Aldrich Fine Chemicals, Merck, Synco Bio Partners

Notes for Editors If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on + 44 (0) 20 7549 9987

About visiongain Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Cancer Diagnostics Market Report 2021-2031

Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.

19 April 2021

Read

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

Read

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

Read

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever